Lv3
300 积分 2025-11-01 加入
French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025
29天前
已完结
Brodalumab: A new way to inhibit IL ‐17 in psoriasis
30天前
已完结
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study
30天前
已完结
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
30天前
已完结
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
30天前
已完结
Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France
30天前
已完结
Psoriasis: Comorbidities
30天前
已完结
14030 Ten-year interim results from the ESPRIT registry: Real-world safety, effectiveness, and patient-reported outcomes of adalimumab for moderate to severe psoriasis
30天前
已关闭
Psoriasis Comorbidities and Their Treatment Impact
30天前
已完结
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions
2个月前
已完结
皖公网安备34019202002308
